Modality
Fusion Protein
MOA
CD3xCD20
Target
GIP-R
Pathway
Hedgehog
HCC
Development Pipeline
Preclinical
~Mar 2021
→ ~Jun 2022
Phase 1
~Sep 2022
→ ~Dec 2023
Phase 2
~Mar 2024
→ ~Jun 2025
Phase 3
Sep 2025
→ Jun 2028
Phase 3Current
NCT06357499
1,828 pts·HCC
2025-09→2028-06·Terminated
1,828 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-172.2y awayPh3 Readout· HCC
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Termina…
Catalysts
Ph3 Readout
2028-06-17 · 2.2y away
HCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06357499 | Phase 3 | HCC | Terminated | 1828 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R |